

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated antibody that comprises at least one amino acid sequence as listed in SEQ ID NOs:1-8 comprising a V_H domain having a CDR1 comprising the sequence set forth in SEQ ID NO:6, a CDR2 comprising the sequence set forth in SEQ ID NO:7, and a CDR3 comprising the sequence set forth in SEQ ID NO:8; and a V_L domain having a CDR1 comprising the sequence set forth in SEQ ID NO:3, a CDR2 comprising the sequence set forth in SEQ ID NO:4, and a CDR3 comprising the sequence set forth in SEQ ID NO:5,
wherein the antibody which can bind to Factor IX/Factor IXa and increase the procoagulation activity of FIXa Factor IXa.

2-7. (Canceled)

3. (Currently amended) The isolated antibody according to claim 1, wherein the antibody V_H domain comprises the sequence set forth in SEQ ID NO: 1 and the V_L domain comprises the sequence set forth in SEQ ID NO:2.

4. (Currently amended) The isolated antibody according to claim 1, wherein the antibody is an IgG antibody.

5. (Currently amended) The isolated antibody according to claim 1, wherein the antibody is a monoclonal antibody.

6. (Currently amended) The isolated antibody according to claim 1, wherein the antibody is an antibody fragment.

7. (Currently amended) The isolated antibody according to claim 1, which wherein the antibody is a recombinant antibody.

8. (Currently amended) The isolated antibody according to claim 12, which wherein the antibody is a single chain antibody.

9. (Currently amended) The isolated antibody according to claim 1, which wherein the antibody is a humanized antibody.

10. (Currently amended) The isolated antibody of claim 1, wherein the antibody is labeled.

11-21. (Canceled)

22. (Currently amended) A pharmaceutical composition comprising an isolated antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.

23. (Currently amended) The pharmaceutical composition comprising the isolated antibody of claim 8 ~~22, wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOS:3-8.~~

24. (Currently amended) The pharmaceutical composition according to claim 23, further comprising a Factor selected from the group consisting of factor Factor IX, factor Factor IX α , factor Factor IX $\alpha\beta$, and/or factor Factor IX, and combinations thereof.

25-27. (Canceled)

28. (New) The pharmaceutical composition according to claim 22, further comprising a Factor selected from the group consisting of Factor IX, Factor IX α , Factor IX $\alpha\beta$, and combinations thereof.